Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCKT 21.98 -0.12(-0.54%)
Will RCKT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCKT
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
Other News for RCKT
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT)
Baron Health Care Fund Q1 2024 Shareholder Letter
RCKT Crosses Below Key Moving Average Level
Optimistic Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Expert Leadership
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)